Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug148 | ASTX660 Wiki | 0.58 |
drug1560 | Exercise Group Wiki | 0.58 |
drug4436 | Tocilizumab Injection Wiki | 0.41 |
Name (Synonyms) | Correlation | |
---|---|---|
D059350 | Chronic Pain NIH | 0.31 |
D058186 | Acute Kidney Injury NIH | 0.11 |
D014947 | Wounds and Injuries NIH | 0.10 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0012532 | Chronic pain HPO | 0.31 |
HP:0001919 | Acute kidney injury HPO | 0.11 |
Navigate: Correlations HPO
There are 3 clinical trials
In this study, defined cases of COVID-19 with mild, moderate or severe pneumonia will be treated with standard treatment regimens in combination with IV injection of Deferoxamine. Improvement in clinical, laboratory and radiological manifestations will be evaluated in treated patient compared to control group.
Description: All cause of death
Measure: Mortality rate Time: up to 20 daysDescription: Mild, Moderate or Severe
Measure: change in patients clinical manifestation Time: up to 20 daysDescription: days
Measure: Length of hospitalization Time: up to 20 daysAssessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, associated with standards treatments in COVID-19 (+) patients, Hospitalized In Intensive care in Tunisia. Multicentric, comparative, randomized study.
Description: Evaluate the mortality rate at 90 days. Evaluate the Intensive Care Unit (ICU) and Hospital Mortality rate at day 90 with date and cause of death (if applicable)
Measure: the mortality rate Time: 90 dayMultiple lines of evidence support a central role of iron in causing acute kidney injury (AKI), including the finding that prophylactic administration of iron chelators attenuates AKI in animal models. Patients undergoing cardiac surgery may be particularly susceptible to iron-mediated kidney injury due to the profound hemolysis that often occurs from cardiopulmonary bypass. The investigators will test in a phase 2, randomized, double-blind, placebo-controlled trial whether prophylactic administration of deferoxamine decreases the incidence of AKI following cardiac surgery.
Description: Urine output <0.5 ml/kg/h for ≥6 consecutive hours, an increase in serum creatinine ≥0.3 mg/dl within the first 48h, an increase in serum creatinine ≥50% in 7 days, or receipt of renal replacement therapy in 7 days.
Measure: Acute Kidney Injury Time: 7 daysDescription: Urine levels of NGAL and KIM-1
Measure: Renal tubular injury Time: 3 daysDescription: Peak postoperative troponin I elevation >10 times the 99th percentile upper reference limit
Measure: Postoperative myocardial injury Time: 2 daysDescription: New onset postoperative atrial fibrillation (patients with atrial fibrillation at baseline will be excluded)
Measure: Atrial fibrillation Time: 7 daysDescription: Requirement for mechanical ventilation >24h postoperatively
Measure: Prolonged mechanical ventilation Time: 24 hoursDescription: Life-threatening organ dysfunction caused by a dysregulated host response to infection. Organ dysfunction is defined as an acute increase in the total SOFA score ≥2 points consequent to the infection.
Measure: Sepsis Time: 7 daysDescription: 28 minus the number of days ventilated. Patients who die within 28 days will be assigned 0 ventilator-free days.
Measure: Ventilator-free days Time: 28 daysDescription: 28 minus the number of days hospitalized. Patients who die within 28 days will be assigned 0 hospital-free days.
Measure: Hospital-free days Time: 28 daysDescription: 28 minus the number of days in the ICU. Patients who die within 28 days will be assigned 0 ICU-free days.
Measure: ICU-free days Time: 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports